Not Just A Beauty Trend, Botox Procedures Need A Medical Approach To Be Safe To Use

Dr. Kyung-tae Bae, Director of It's Me Clinic Sejong branch, South Korea, showed the latest injection techniques to Indonesian doctors. (doc. Daewoong Pharmaceutical)

JAKARTA - Botoxes or botulinum toxins are increasingly known as one of the aesthetic treatments that people are in great demand. This procedure is used to reduce wrinkles and fine lines on the face by temporarily weakening certain muscles.

Although popular, the use of botoks still requires adequate education, both for patients and medical personnel, because this procedure is closely related to anatomy, dose, and appropriate injection techniques. Mistreatment can actually cause detrimental side effects.

In line with the importance of education, several companies in the pharmaceutical and aesthetic fields have contributed to improving the knowledge of medical practitioners in Indonesia.

One of them is the collaboration between Daewoong Pharmaceutical and CGBIO Indonesia which participated in the AMUSE 2025 event (Aesthetic Medicine Update Seminar and Exhibition), an international medical aesthetic congress held on 17 June 22, 2025 in Jakarta and Tangerang.

In the event, they introduced a combination procedure training program, which is designed to improve the skills of doctors in using aesthetic products appropriately.

More than 1,200 doctors from various specialization backgrounds such as dermatology, plastic surgery, and aesthetics attended this event. Direct training was also provided by some experts from South Korea, such as Dr. Kyung-tae Bae and Dr. Jae-yoon Jung, who presented a combination treatment strategy according to the patient's condition.

Dr. Jae-yoon Jung, Director of Oaro Dermatology at Nowon branch, South Korea, conveyed his education on a combination treatment strategy using the CaHA (Facetem)-based botulinous and skin booster toxine.

"This session is a valuable opportunity to introduce a combination treatment method adapted to the patient's condition to get more optimal results," explained Dr. Jae-yoon Jung in his statement.

The training also highlighted the use of pure botulinum toxine, a skin booster made from calcium hydrokapatite (CaHA), a filler based on hyaluronic acid (HA), and a polydioxanone (PDO) medical thread for facial distancing procedures.

"By utilizing Daewoong and CGBIO's globally recognized medical aesthetic portfolio, we will continue to localize and develop a combination procedure that fits the Indonesian market. Through educational programs, we hope to provide continuous and deep professional training for local medical personnel," said Changwoo Ha, Head of the Medical Aesthetic Business Division at KIIMOT.

This training program is part of the DEEP (Daewoong Expert Education Program) initiative which aims to enrich the clinical and technical knowledge of medical personnel in Indonesia. This activity is supported by KIIMOT (Korea-Indonesia Integrated Marketing Operation Taskforce), which focuses on developing cross-border aesthetic education.

Although still in the market development stage, the company said that the official launch of the botulinnum toxine product in Indonesia is scheduled for July 2025. However, what is emphasized is not just product marketing, but an improvement in the quality of education and clinical practice of local medical personnel so that aesthetic care can be carried out safely, effectively, and ethically.